SCHEMBL2735367

SCHEMBL2735367

Cc1ccc(NC(=O)c2nc[nH]c2C(=O)Nc2nc3cc(OCC(=O)NC4CCCCC4)ccc3[nH]2)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
ALDH1A1 P00352 2/20 0.41
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.39
MAPT P10636 3/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
USP2 O75604 1/20 0.38
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
P2RY12 Q9H244 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL215041 0.88 KMT2A (0.43) KMT2AMEN1LMNAHPGDALDH1A1
SCHEMBL214444 0.85 KMT2A (0.41) KMT2AMEN1LMNAHPGDALDH1A1
SCHEMBL215377 0.84 ALDH1A1 (0.44) KMT2AMEN1LMNAHPGDALDH1A1
SCHEMBL214561 0.83 MAPT (0.51) KMT2AMEN1LMNAALDH1A1RAB9A
SCHEMBL214815 0.83 MAPT (0.41) KMT2AMEN1LMNAHPGDALDH1A1
SCHEMBL2735364 0.83 MAPT (0.43) KMT2AMEN1LMNAHPGDALDH1A1
SCHEMBL213494 0.83 KMT2A (0.43) KMT2AMEN1LMNAHPGDALDH1A1
SCHEMBL2735402 0.83 KMT2A (0.39) KMT2AMEN1LMNAHPGDALDH1A1
Hydrochloric Acid SCHEMBL215296 0.83 MAPT (0.40) KMT2AMEN1LMNAHPGDALDH1A1
SCHEMBL215480 0.82 MAPT (0.44) KMT2AMEN1LMNAHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 EP claimed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO claimed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 KMT2A 437/4885MEN1 3504/4885LMNA 4821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.